Featured

Status

All Statuses
  • Active, not recruiting8

Health Topics

Any Category
Chemicals and Drugs
Heterocyclic Compounds
Clear Filters

Search Clinical Trials

8 Results
Active, Not Recruiting
Post IVIG Medication in Children With Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is the most common acquired immune cytopenia in childhood, affecting 4-6 in 100,000 children. The pathophysiology of ITP is highly complex and incompletely understood. Accepted mechanisms include …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy …
Baylor Role: Collaborator
Active, Not Recruiting
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Patients give blood to make GD2-T cells that are grown and frozen. To get the GD2-CAR to attach to the surface of the T-cell, a gene is inserted into the …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum …
Baylor Role: Collaborator
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Active, Not Recruiting
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role: Lead Sponsor